University of Missouri Health Care has started using an FDA-approved targeted radioactive medicine called Pluvicto for the treatment of advanced metastatic prostate cancer. Pluvicto includes lutetium-177 (Lu-177), a radioisotope produced only in the United States at the University of Missouri Research Reactor (MURR). The treatment shows promise for patients whose prostate cancer continues to progress after other interventions, such as chemotherapy and hormonal therapy. It involves a total of six injections spaced six weeks apart and takes less than 10 minutes per injection. MURR has entered into an exclusive agreement with Advanced Accelerator Applications International to provide Lu-177. Pluvicto has received FDA approval and may be offered widely in the future.
Wed, 13 Dec 2023 16:53:34 GMT | University of Missouri